XF-73 is ‘The Real Deal’
With Destiny’s lead drug now licensed to Sebela Pharmaceuticals in preparation for its Phase 3 study, Destiny’s second Phase 3-ready drug (XF-73) is next up for partnering and the recent publication and XF Pipeline Update burnished its profile for the benefit of investors and potential partners. As one key opinion leader at the event noted, 'XF-73 is the real deal.'Destiny announced the publication of a microbiological study that tested XF-73’s activity against more than 2,500 clinical isolates of Staphylococci. XF-73 was found to be active against all isolates tested, irrespective of whether they were sensitive or resistant to 22 other antibiotics. This expands XF-73’s existing profile and earlier data.
This is important to regulators since, in contrast to XF-73, the most commonly used antibiotic for nasal decolonisation – mupirocin calcium (Bactroban Nasal) – does have a resistance problem, illustrated soon after it became available over the counter in New Zealand (resulting in its withdrawal), and by the very narrow label given to Bactroban Nasal by the FDA. It is also important that the publication demonstrated XF-73’s activity not just against MDR S.aureus strains, including MRSA, but against 15 other staphylococcal species.
We provide our summary of Destiny’s XF Pipeline Update and presentations in the body of this note and our Fair Value for Destiny Pharma plc remains unchanged at £254.7m (or 279 pence per share).
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.